ES2544967T3 - Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas - Google Patents

Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas Download PDF

Info

Publication number
ES2544967T3
ES2544967T3 ES09720545.4T ES09720545T ES2544967T3 ES 2544967 T3 ES2544967 T3 ES 2544967T3 ES 09720545 T ES09720545 T ES 09720545T ES 2544967 T3 ES2544967 T3 ES 2544967T3
Authority
ES
Spain
Prior art keywords
bone
treatment
prevention
formulation
metastases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09720545.4T
Other languages
English (en)
Inventor
Vanessa Bourgeaux
Yann Godfrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Application granted granted Critical
Publication of ES2544967T3 publication Critical patent/ES2544967T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Suspensión de glóbulos rojos que encapsulan un bisfosfonato de segunda generación o de tercera generación, en la que los glóbulos rojos que encapsulan el bisfosfonato han experimentado un tratamiento químico con un agente químico para promover el direccionamiento de la médula ósea, para su uso como un medicamento para la prevención y el tratamiento de las metástasis óseas.

Description

01
ES09720545.4T 2008-03-10 2009-03-10 Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas Active ES2544967T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0851521 2008-03-10
FR0851521A FR2928270B1 (fr) 2008-03-10 2008-03-10 Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
PCT/EP2009/052792 WO2009112493A1 (en) 2008-03-10 2009-03-10 Formulation and method for the prevention and treatment of bone metastases or other bone diseases

Publications (1)

Publication Number Publication Date
ES2544967T3 true ES2544967T3 (es) 2015-09-07

Family

ID=39865428

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09720545.4T Active ES2544967T3 (es) 2008-03-10 2009-03-10 Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas

Country Status (13)

Country Link
US (3) US20110014171A1 (es)
EP (1) EP2249816B1 (es)
JP (1) JP6034001B2 (es)
KR (1) KR101604451B1 (es)
CN (1) CN101965182B (es)
AU (1) AU2009224681B2 (es)
CA (1) CA2718028C (es)
ES (1) ES2544967T3 (es)
FR (1) FR2928270B1 (es)
HK (1) HK1152883A1 (es)
IL (1) IL207713A (es)
PL (1) PL2249816T3 (es)
WO (1) WO2009112493A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
MX2016010835A (es) 2014-02-21 2017-07-11 Anokion Sa Terapeuticos dirigidos a la glucosa.
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
JP2016025177A (ja) * 2014-07-18 2016-02-08 トヨタ自動車株式会社 スイッチング素子
HRP20220147T1 (hr) 2016-01-11 2022-04-15 Rubius Therapeutics, Inc. Pripravci i postupci povezani s multimodalnim terapijskim staničnim sustavima za indikacije raka
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
ES2867230T3 (es) * 2016-10-26 2021-10-20 Biointelligence Systems S L Composición bioactiva ósea y usos de la misma
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CN110568114B (zh) * 2019-08-29 2021-12-28 福州佳宸生物科技有限公司 唑来膦酸和利塞膦酸的固相微萃取-高效液相色谱在线联用检测方法
WO2021228832A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
CN112790155A (zh) * 2021-02-01 2021-05-14 华中科技大学同济医学院附属协和医院 一种验证sag预防环境异常相关性骨发育不良的方法
CN115400145B (zh) * 2021-05-26 2024-04-30 北京罗诺强施医药技术研发中心有限公司 治疗和预防骨质疏松症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
EP0882448B1 (en) * 1997-05-05 2005-01-12 DIDECO S.r.l. Method of encapsulating biologically active agents within erythrocytes and apparatus therefor
CN1771972A (zh) * 2004-11-09 2006-05-17 胡才忠 氯屈膦酸脂质体及其制剂
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
WO2008016172A1 (fr) * 2006-08-04 2008-02-07 Kurume University Inhibiteur de métastase
CA2715379A1 (en) * 2008-02-13 2009-08-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease

Also Published As

Publication number Publication date
CN101965182A (zh) 2011-02-02
EP2249816B1 (en) 2015-05-20
JP2011513464A (ja) 2011-04-28
PL2249816T3 (pl) 2015-10-30
CA2718028C (en) 2016-08-30
AU2009224681B2 (en) 2012-01-12
AU2009224681A1 (en) 2009-09-17
FR2928270B1 (fr) 2011-01-21
IL207713A0 (en) 2010-12-30
US20140010795A1 (en) 2014-01-09
FR2928270A1 (fr) 2009-09-11
JP6034001B2 (ja) 2016-11-30
WO2009112493A1 (en) 2009-09-17
US20140363413A1 (en) 2014-12-11
CA2718028A1 (en) 2009-09-17
US20110014171A1 (en) 2011-01-20
HK1152883A1 (en) 2012-03-16
KR20100129288A (ko) 2010-12-08
EP2249816A1 (en) 2010-11-17
IL207713A (en) 2016-10-31
CN101965182B (zh) 2012-05-23
KR101604451B1 (ko) 2016-03-17

Similar Documents

Publication Publication Date Title
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CL2017000498A1 (es) Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
CO6571886A2 (es) Antagonistas de pcsk9
DOP2012000314A (es) Compuestos, composiciones de tiocetato y metodos de uso
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
CR11723A (es) Agente para tratar enfermedad
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
BR112015007083A2 (pt) inibidores de histona demetilases
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
MX362375B (es) Extracto de saliva entera de sanguijuela.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
CO6680710A2 (es) Impalnte con calcio en superficie, y método de modificación de la superficie de un impalnte para dotar a dicha superficie de calcio
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.